Acute Care
Flags- Red, yellow and beyond

Nasal canula, HFNC, BiPAP, CPAP, Vent

Complete & Continue Next Lesson Learn More

Bedside Mini-Table (Targets & Escalation)

Parameter / Scenario Typical Target / Threshold What to Do
SpO₂ (most adults) Goal ~92–96% Use conventional O₂; avoid both hypoxia and hyperoxia.
SpO₂ (COPD CO₂ retainer) Goal 88–92% Titrate O₂ cautiously; watch for rising PaCO₂ if ABG/VBG available.
Hypoxemic AHRF (nonhypercapnic), high flow need FiO₂ >0.4 or persistent RR ≥28 Escalate to HFNC (preferred) or consider CPAP per etiology/resources.
COPD exacerbation with acidosis pH ≤7.35 and PaCO₂ elevated Start BiPAP (NIV). Expect ↓ intubations & mortality vs O₂ alone.
Cardiogenic pulmonary edema Severe dyspnea, hypoxemia CPAP/BiPAP for rapid relief + diuretics/vasodilators; mortality neutral.
COVID-19 hypoxemic AHRF Failure on conventional O₂ CPAP reduces intubation/death vs O₂ in RCT; HFNC often useful.
Failure of noninvasive support Worsening pH/PaCO₂, rising RR/FiO₂, fatigue, AMS Intubate—avoid harmful delay after NIV/HFNC failure.
MAP (organ perfusion) Keep ≥65 mmHg If <65, treat shock first; defer aggressive mobilization.
ABG pointers PaO₂ ≥60; pH 7.35–7.45; PaCO₂ 35–45 Use ABG to confirm oxygenation/ventilation; VBG ok for pH/CO₂ when O₂ not the question.

Guide aligns with major RCTs (~2005–2025). Always pair with clinical judgment and local protocols.

Quick Comparison (when each modality fits)

ScenarioPreferred SupportWhy / RCT signal
Mild–moderate hypoxemia, low work of breathing, no hypercapnic acidosis Conventional Oxygen Targets SpO₂ 92–96% without high flows; avoid hyperoxia/hypoxia.
Acute hypoxemic respiratory failure (nonhypercapnic), high flow/FiO₂ needs HFNC FLORALI: improved comfort/intubation in the sickest; survival signal vs O₂/NIV.
COVID-19 hypoxemic AHRF needing more than O₂ CPAP (consider HFNC) RECOVERY-RS: CPAP lowered intubation/death vs conventional O₂; HFNC not superior to O₂ for that composite.
COPD exacerbation with hypercapnic acidosis (pH ≤7.35) BiPAP (NIV) Consistent RCT/meta-evidence: lower intubation and mortality.
Cardiogenic pulmonary edema with severe distress CPAP or BiPAP + meds 3CPO: faster physiologic relief & fewer intubations; mortality neutral.
Failure of noninvasive support; airway threat; severe acidosis or fatigue Invasive Mechanical Ventilation Escalate to protect airway and control gas exchange; avoid delays.

Essay (evidence-driven summary)

1) When oxygen alone is appropriate

  • Clinical picture: Mild–moderate hypoxemia, modest work of breathing, intact mentation, no hypercapnic acidosis.
  • Targets: Aim SpO₂ ≈ 92–96% (avoid both hypoxia and hyperoxia).
  • Evidence signal: ICU oxygen strategy trials: no uniform mortality advantage for extreme conservatism vs usual—steer between extremes, reassess often.

2) When to step up to a noninvasive device

HFNC: Best for acute hypoxemic respiratory failure (AHRF) without major hypercapnia.

  • Delivers heated, humidified high-flow O₂ with reliable FiO₂ + low-level PEEP; reduces work of breathing.
  • FLORALI: improved comfort/intubation in sickest subgroup; survival signal vs O₂/NIV.
  • Post-extubation: HFNC reduced reintubation vs conventional O₂ (low-risk) and was non-inferior to NIV (high-risk) in JAMA 2016 trials.

CPAP/BiPAP (NIV):

  • COPD + acidosis: Bilevel NIV lowers intubation & mortality.
  • Cardiogenic pulmonary edema: NIV rapidly improves physiology; mortality neutral in 3CPO—use as adjunct with meds.
  • Hypoxemic AHRF (non-COPD): Mixed; CPAP beat conventional O₂ in COVID AHRF (RECOVERY-RS); HFNC preferred in nonhypercapnic AHRF (FLORALI).
  • Requirements: Cooperative patient, protected airway, experienced staff and monitoring.

3) When to proceed to invasive mechanical ventilation

  • Refractory hypoxemia/hypercapnia with acidosis despite optimized noninvasive support.
  • Inability to protect airway; impending/actual arrest; severe fatigue/AMS.
  • Hemodynamic instability/multi-organ failure requiring controlled ventilation.
  • Follow failure thresholds used in trials to avoid delayed intubation harms.

References (key randomized evidence, ~2005–2025)

  1. Frat J-P, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure (FLORALI). NEJM. 2015.
  2. Perkins GD, et al. CPAP vs HFNC vs conventional oxygen in COVID-19 AHRF (RECOVERY-RS). JAMA/Lancet Respir Med. 2021–2022.
  3. Gray A, et al. Non-invasive ventilation in cardiogenic pulmonary oedema (3CPO). NEJM/Lancet. 2008–2009.
  4. Hernández G, et al. HFNC vs conventional O₂ after extubation (low-risk) & HFNC non-inferior to NIV (high-risk). JAMA. 2016.
  5. Mackle D, et al. Conservative vs usual oxygen in ventilated ICU patients (ICU-ROX). NEJM. 2020.
  6. ERS/ATS Clinical Practice Guideline (2017): Noninvasive ventilation for acute respiratory failure (COPD acidosis). Eur Respir J. 2017.